Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB1891

Introduced
5/22/25  

Caption

PILLS Act Producing Incentives for Long-term production of Lifesaving Supply of medicine Act

Impact

The implementation of SB1891 is expected to have a significant impact on the pharmaceutical sector by creating a more favorable economic environment for the production of generic drugs and biosimilars. By offering credits equal to a percentage of the value added to eligible components produced in the U.S., the bill is designed to incentivize domestic manufacturing. This could, in turn, help lower drug costs for consumers and enhance market competition, potentially increasing access to lifesaving medications.

Summary

SB1891, known as the Producing Incentives for Long-term production of Lifesaving Supply of medicine Act (PILLS Act), aims to amend the Internal Revenue Code of 1986 by establishing tax credits to encourage the domestic production of generic drugs and biosimilars. This bill seeks to provide economic incentives for pharmaceutical companies to manufacture these essential medications in the United States, aiming to reduce reliance on foreign production and to enhance the availability of affordable drugs for patients.

Contention

However, the bill might not be without contention. Critics may express concerns about the potential for manufacturers to take advantage of tax credits without ensuring the quality or availability of drugs. There could also be fears that the focus on incentivizing domestic production may lead to increased regulatory scrutiny or burdens on companies, particularly smaller manufacturers that might struggle with compliance costs. Additionally, the bill's safeguards against benefiting foreign entities of concern, as defined in relevant defense legislation, may raise discussions about the balance of national security interests with pharmaceutical availability.

Companion Bills

US HB1396

Same As PILLS Act Producing Incentives for Long-term production of Lifesaving Supply of medicine Act

Previously Filed As

US HB6109

PILLS Act Producing Incentives for Long-term production of Lifesaving Supply of Medicine Act

US HB8503

DUALS Act of 2024 Delivering Unified Access to Lifesaving Services Act of 2024

US SB5419

Protecting Our Essential Medicines Act

US SB2129

Ensuring Access to Lower-Cost Medicines for Seniors Act

US HB9745

Lifesaving Gear for Police Act of 2024

US SB1269

INSULIN Act of 2023 Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2023

US HB7709

PREPARE ACT of 2024 Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines Act of 2024

US HB10494

To amend the Internal Revenue Code of 1986 to establish a tax credit to incentivize the purchase of American agricultural commodities.

US HB5461

Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023

US SB3950

DUALS Act of 2024 Delivering Unified Access to Lifesaving Services Act of 2024

Similar Bills

US HB1396

PILLS Act Producing Incentives for Long-term production of Lifesaving Supply of medicine Act

US SB1954

Biosimilar Red Tape Elimination Act

US SB5459

A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.

US SB1096

Preserve Access to Affordable Generics and Biosimilars Act

US SB1040

Drug Competition Enhancement Act

US HB9184

Patient Access Act of 2024

US HB3546

Prescription Drug Price Relief Act of 2025

US SB1818

Prescription Drug Price Relief Act of 2025